Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 13Urinary Bladder Neoplasms 11Ovarian Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 5Colorectal Neoplasms 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Recurrence 2Rectal Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Gallbladder Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 5Gemcitabine 4Oxaliplatin 2Irinotecan 2Fluorouracil 2Capecitabine 2Bevacizumab 2zanidatamab 1toripalimab 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1fludarabine 1envafolimab 1encorafenib 1durvalumab 1binimetinib 1Trastuzumab 1Pemetrexed 1Nivolumab 1Folfox protocol 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Gemcitabine × 30 days × Clear all
NCT07619235 2026-06-01

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Huazhong University of Science and Technology

Phase 4 Not yet recruiting
32 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06465563 2026-05-29

SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2 Active not recruiting
93 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07599995 2026-05-20

GENE

Sir Run Run Shaw Hospital

Phase 2 Not yet recruiting
34 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡